SARS-CoV-2 Vaccination-Induced Thrombotic Thrombocytopenia: A Rare But Serious Immunologic Complication.
Annu Rev Med
; 2022 Jul 18.
Article
in English
| MEDLINE | ID: covidwho-2227028
ABSTRACT
Billions of individuals worldwide have benefited from the unprecedented large-scale rollout of COVID-19 vaccines. Given the sheer number of people that have received these vaccines, it is not surprising that rare side effects are reported that were not previously detected in the phase III vaccine trials. This review addresses one rare complication called SARS-CoV-2 vaccination-induced thrombotic thrombocytopenia (VITT). It occurs in approximately 1/50,000 to 1/100,000 recipients of the adenovirus vector-based COVID-19 vaccines made by AstraZeneca-Oxford or Johnson & Johnson. Information on VITT syndrome was disseminated quickly via social media and publications after it was first discovered. Initial observations associating VITT with specific patient populations, thrombus locations, and outcomes associated with heparin therapy have since been refined with additional clinical experience. In this review, we discuss what is currently known about the incidence, pathophysiology, diagnosis, and treatment of VITT. Expected final online publication date for the Annual Review of Medicine, Volume 74 is January 2023. Please see http//www.annualreviews.org/page/journal/pubdates for revised estimates.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Observational study
/
Prognostic study
Topics:
Vaccines
Language:
English
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS